CoChat
Sign Up
Cited by 25Advanced Proteomics Techniques and ApplicationsHepatocellular Carcinoma Treatment and PrognosisCholangiocarcinoma and Gallbladder Cancer Studies

Proteome Landscapes of Human Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma

Open access
Yi, Xiao, Zhu, Jiang, Liu, Wei, Peng, Li, Lu, Cong, Sun, Ping, Huang, Lingling, Nie, Xiu +3 more·2023·Molecular & Cellular Proteomics
DOI 10.1016/j.mcpro.2023.100604PMC PMC10413158
Open this paper in CoChat — free account

Abstract

Liver cancer is among the top leading causes of cancer mortality worldwide. Particularly, hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (CCA) have been extensively investigated from the aspect of tumor biology. However, a comprehensive and systematic understanding of the molecular characteristics of HCC and CCA remains absent. Here, we characterized the proteome landscapes of HCC and CCA using the data-independent acquisition (DIA) mass spectrometry (MS) method. By comparing the quantitative proteomes of HCC and CCA, we found several differences between the two cancer types. In particular, we found an abnormal lipid metabolism in HCC and activated extracellular matrix-related pathways in CCA. We next developed a three-protein classifier to distinguish CCA from HCC, achieving an area under the curve (AUC) of 0.92, and an accuracy of 90% in an independent validation cohort of 51 patients. The distinct molecular characteristics of HCC and CCA presented in this study provide new insights into the tumor biology of these two major important primary liver cancers. Our findings may help develop more efficient diagnostic approaches and new targeted drug treatments.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.mcpro.2023.100604

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • An opposite, pro-oncogenic role for TBX3 has been revealed in other tumor types, such as malignant melanoma, breast, gastric, and cervical cancers.

    “An opposite, pro-oncogenic role for TBX3 has been revealed in other tumor types, such as malignant melanoma, breast, gastric, and cervical cancers [1–3].”

    From Overexpression of TBX3 suppresses tumorigenesis in experimental and human cholangiocarcinoma (2024) · cites this paper as [3]

    The Results and Discussion section examines protein expression in hepatocellular carcinoma and cholangiocarcinoma, not TBX3’s role in the cancers named in the claim. Searches for TBX3 and for an oncogenic role in melanoma, breast, gastric, and cervical cancers found no passage addressing that point in our copy. (LLM, conf=0.76)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 50

  1. [1]Sung H. Ferlay J. Siegel R.L. Laversanne M. Soerjomataram I. Jemal A. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J. Clin. 71 2021 209 249 33538338
  2. [2]Yang J.D. Hainaut P. Gores G.J. Amadou A. Plymoth A. Roberts L.R. A global view of hepatocellular carcinoma: trends, risk, prevention and management Nat. Rev. Gastroenterol. Hepatol. 16 2019 589 604 31439937 PMC6813818
  3. [3]Banales J.M. Marin J.J.G. Lamarca A. Rodrigues P.M. Khan S.A. Roberts L.R. Cholangiocarcinoma 2020: the next horizon in mechanisms and management Nat. Rev. Gastroenterol. Hepatol. 17 2020 557 588 32606456 PMC7447603
  4. [4]Lee Y.T. Wang J.J. Luu M. Noureddin M. Nissen N.N. Patel T.C. Comparison of clinical features and outcomes between intrahepatic cholangiocarcinoma and hepatocellular carcinoma in the United States Hepatology 74 2021 2622 2632 34114675
  5. [5]Kuhlmann J.B. Euringer W. Spangenberg H.C. Breidert M. Blum H.E. Harder J. Treatment of unresectable cholangiocarcinoma: conventional transarterial chemoembolization compared with drug eluting bead-transarterial chemoembolization and systemic chemotherapy Eur. J. Gastroenterol. Hepatol. 24 2012 437 443 22261548
  6. [6]Marrero J.A. Kulik L.M. Sirlin C.B. Zhu A.X. Finn R.S. Abecassis M.M. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases Hepatology 68 2018 723 750 29624699
  7. [7]Mavros M.N. Economopoulos K.P. Alexiou V.G. Pawlik T.M. Treatment and prognosis for patients with intrahepatic cholangiocarcinoma: systematic review and meta-analysis JAMA Surg. 149 2014 565 574 24718873
  8. [8]Palmer W.C. Patel T. Are common factors involved in the pathogenesis of primary liver cancers? a meta-analysis of risk factors for intrahepatic cholangiocarcinoma J. Hepatol. 57 2012 69 76 22420979 PMC3804834
  9. [9]General Office of National Health Commission Standard for diagnosis and treatment of primary liver cancer (2022 edition) Chin. J. Clin. Hepatol. 38 2022 288 303
  10. [10]Chaisaingmongkol J. Budhu A. Dang H. Rabibhadana S. Pupacdi B. Kwon S.M. Common molecular subtypes among asian hepatocellular carcinoma and cholangiocarcinoma Cancer Cell 32 2017 57 70.e3 28648284 PMC5524207
  11. [11]Jiang Y. Sun A. Zhao Y. Ying W. Sun H. Yang X. Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma Nature 567 2019 257 261 30814741
  12. [12]Gao Q. Zhu H. Dong L. Shi W. Chen R. Song Z. Integrated proteogenomic characterization of HBV-related hepatocellular carcinoma Cell 179 2019 1240 31730861
  13. [13]Dong L. Lu D. Chen R. Lin Y. Zhu H. Zhang Z. Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma Cancer Cell 40 2022 70 87.e15 34971568
  14. [14]Zhu T. Zhu Y. Xuan Y. Gao H. Cai X. Piersma S.R. DPHL: a DIA pan-human protein mass spectrometry library for robust biomarker discovery Genomics Proteomics Bioinformatics 18 2020 104 119 32795611 PMC7646093
  15. [15]Zhu Y. Weiss T. Zhang Q. Sun R. Wang B. Yi X. High-throughput proteomic analysis of FFPE tissue samples facilitates tumor stratification Mol. Oncol. 13 2019 2305 2328 31495056 PMC6822243
  16. [17]Cai X. Xue Z. Wu C. Sun R. Qian L. Yue L. High-throughput proteomic sample preparation using pressure cycling technology Nat. Protoc. 17 2022 2307 2325 35931778 PMC9362583
  17. [18]Cai X. Ge W. Yi X. Sun R. Zhu J. Lu C. PulseDIA: data-independent acquisition mass spectrometry using multi-injection pulsed gas-phase fractionation J. Proteome Res. 20 2021 279 288 32975123
  18. [19]Zhang F. Yu S. Wu L. Zang Z. Yi X. Zhu J. Phenotype classification using proteome data in a data-independent acquisition tensor format J. Am. Soc. Mass Spectrom. 31 2020 2296 2304 33104352
  19. [20]Bruderer R. Bernhardt O.M. Gandhi T. Miladinovic S.M. Cheng L.Y. Messner S. Extending the limits of quantitative proteome profiling with data-independent acquisition and application to acetaminophen-treated three-dimensional liver microtissues Mol. Cell. Proteomics 14 2015 1400 1410 25724911 PMC4424408
  20. [21]Ge W. Liang X. Zhang F. Hu Y. Xu L. Xiang N. Computational optimization of spectral library size improves DIA-MS proteome coverage and applications to 15 tumors J. Proteome Res. 20 2021 5392 5401 34748352
  21. [22]Rost H.L. Rosenberger G. Navarro P. Gillet L. Miladinovic S.M. Schubert O.T. OpenSWATH enables automated, targeted analysis of data-independent acquisition MS data Nat. Biotechnol. 32 2014 219 223 24727770
  22. [23]Chi H. Liu C. Yang H. Zeng W.F. Wu L. Zhou W.J. Comprehensive identification of peptides in tandem mass spectra using an efficient open search engine Nat. Biotechnol. 2018 10.1038/nbt.4236 30295672 · DOI
  23. [24]Demichev V. Messner C.B. Vernardis S.I. Lilley K.S. Ralser M. DIA-NN: neural networks and interference correction enable deep proteome coverage in high throughput Nat. Methods 17 2020 41 44 31768060 PMC6949130
  24. [25]Searle B.C. Pino L.K. Egertson J.D. Ting Y.S. Lawrence R.T. MacLean B.X. Chromatogram libraries improve peptide detection and quantification by data independent acquisition mass spectrometry Nat. Commun. 9 2018 5128 30510204 PMC6277451
  25. [26]Cox J. Mann M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification Nat. Biotechnol. 26 2008 1367 1372 19029910
  26. [27]Krämer A. Green J. Pache L. Pollard J. Jr Tugendreich S. Causal analysis approaches in Ingenuity Pathway Analysis Bioinformatics 30 2013 523 530 24336805 PMC3928520
  27. [28]Zhou Y. Zhou B. Pache L. Chang M. Khodabakhshi A.H. Tanaseichuk O. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets Nat. Commun. 10 2019 1523 30944313 PMC6447622
  28. [31]Zhang F. Ge W. Ruan G. Cai X. Guo T. Data-independent acquisition mass spectrometry-based proteomics and software tools: a glimpse in 2020 Proteomics 20 2020 e1900276 32275110
  29. [32]Navarro P. Kuharev J. Gillet L.C. Bernhardt O.M. MacLean B. Röst H.L. A multicenter study benchmarks software tools for label-free proteome quantification Nat. Biotechnol. 34 2016 1130 1136 27701404 PMC5120688
  30. [33]Insua-Rodriguez J. Oskarsson T. The extracellular matrix in breast cancer Adv. Drug Deliv. Rev. 97 2016 41 55 26743193
  31. [34]Karamanos N.K. Piperigkou Z. Passi A. Gotte M. Rousselle P. Vlodavsky I. Extracellular matrix-based cancer targeting Trends Mol. Med. 27 2021 1000 1013 34389240
  32. [35]Kai F. Drain A.P. Weaver V.M. The extracellular matrix modulates the metastatic journey Dev. Cell 49 2019 332 346 31063753 PMC6527347
  33. [36]Sangineto M. Villani R. Cavallone F. Romano A. Loizzi D. Serviddio G. Lipid metabolism in development and progression of hepatocellular carcinoma Cancers (Basel) 12 2020 1419 32486341 PMC7352397
  34. [37]Liu G. Liu G. Cui X. Xu Y. Transcriptomic data analyses reveal a reprogramed lipid metabolism in HCV-derived hepatocellular cancer Front. Cell Dev. Biol. 8 2020 581863 33195224 PMC7652758
  35. [38]Uhlen M. Fagerberg L. Hallstrom B.M. Lindskog C. Oksvold P. Mardinoglu A. Proteomics. Tissue-based map of the human proteome Science 347 2015 1260419 25613900
  36. [39]Peng H. Yan Z. Zeng X. Zhang S. Jiang H. Huang H. Serum and tissue proteomic signatures of patients with hepatocellular carcinoma using 2D gel electrophoresis Mol. Med. Rep. 20 2019 1025 1038 31173207 PMC6625405
  37. [40]Liu Z. Zhang C. Lee S. Kim W. Klevstig M. Harzandi A.M. Pyruvate kinase L/R is a regulator of lipid metabolism and mitochondrial function Metab. Eng. 52 2019 263 272 30615941
  38. [41]Zhu Y. Zhu J. Lu C. Zhang Q. Xie W. Sun P. Identification of protein abundance changes in hepatocellular carcinoma tissues using PCT-SWATH Proteomics Clin. Appl. 13 2019 e1700179 30365225
  39. [42]Conte F. van Buuringen N. Voermans N.C. Lefeber D.J. Galactose in human metabolism, glycosylation and congenital metabolic diseases: time for a closer look Biochim. Biophys. Acta Gen. Subj. 1865 2021 129898 33878388
  40. [43]Tang M. Etokidem E. Lai K. The Leloir pathway of galactose metabolism - a novel therapeutic target for hepatocellular carcinoma Anticancer Res. 36 2016 6265 6271 27919945
  41. [44]Bian X. Liu R. Meng Y. Xing D. Xu D. Lu Z. Lipid metabolism and cancer J. Exp. Med. 218 2021 e20201606 PMC7754673 33601415
  42. [45]Leonardi G.C. Candido S. Cervello M. Nicolosi D. Raiti F. Travali S. The tumor microenvironment in hepatocellular carcinoma (review) Int. J. Oncol. 40 2012 1733 1747 22447316
  43. [46]Bandyopadhyay S. Zhan R. Wang Y. Pai S.K. Hirota S. Hosobe S. Mechanism of apoptosis induced by the inhibition of fatty acid synthase in breast cancer cells Cancer Res. 66 2006 5934 5940 16740734
  44. [47]Li L. Che L. Tharp K.M. Park H.M. Pilo M.G. Cao D. Differential requirement for de novo lipogenesis in cholangiocarcinoma and hepatocellular carcinoma of mice and humans Hepatology 63 2016 1900 1913 26910791 PMC4874885
  45. [48]Loomba R. Mohseni R. Lucas K.J. Gutierrez J.A. Perry R.G. Trotter J.F. TVB-2640 (FASN Inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a randomized, placebo-controlled phase 2a trial Gastroenterology 161 2021 1475 1486 34310978
  46. [49]Ferdinandusse S. Denis S. IJlst L. Dacremont G. Waterham H.R. Wanders R.J. Subcellular localization and physiological role of alpha-methylacyl-CoA racemase J. Lipid Res. 41 2000 1890 1896 11060359
  47. [50]Xu B. Cai Z. Zeng Y. Chen L. Du X. Huang A. alpha-Methylacyl-CoA racemase (AMACR) serves as a prognostic biomarker for the early recurrence/metastasis of HCC J. Clin. Pathol. 67 2014 974 979 25092674 PMC4215266
  48. [51]Kim J. Kim J. Yoon S. Joo J. Lee Y. Lee K. S100A6 protein as a marker for differential diagnosis of cholangiocarcinoma from hepatocellular carcinoma Hepatol. Res. 23 2002 274 12191675
  49. [52]Li Z. Tang M. Ling B. Liu S. Zheng Y. Nie C. Increased expression of S100A6 promotes cell proliferation and migration in human hepatocellular carcinoma J. Mol. Med. (Berl.) 92 2014 291 303 24281831
  50. [53]Song D. Xu B. Shi D. Li S. Cai Y. S100A6 promotes proliferation and migration of HepG2 cells via increased ubiquitin-dependent degradation of p53 Open Med. (Wars.) 15 2020 317 326 33335992 PMC7712203

Cited by

Sorted by citations

Authors
Yi, X., Zhu, J., Liu, W., Peng, L., Lu, C., Sun, P., Huang, L., Nie, X., Huang, S., Guo, T., & Zhu, Y.
Affiliations
  • Westlake University (CN)
  • Wuhan Union Hospital (CN)
  • Zhejiang Library (CN)
  • Huazhong University of Science and Technology (CN)
Corresponding author
  • Guo, Tiannan
  • Zhu, Yi
ORCID
Venue
Molecular & Cellular Proteomics
Publisher
Elsevier BV
Published
2023-08
Volume
22
Issue
8
Pages
100604
ISSN
1535-9476 (ISSN-L)
DOI
10.1016/j.mcpro.2023.100604
PMC
PMC10413158
OpenAlex
W4381548205
Cited by
25
References
2
Citations by year
2026: 7 · 2025: 8 · 2024: 10
FWCI
2.31
Type
journal article
Language
en
Open access
Licence
Locations
  • Molecular & Cellular Proteomics (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • National Natural Science Foundation of China (21904107)
  • National Key Research and Development Program of China (2021YFA1301602, 2022YF0608403)
Topics
  • Physical Sciences › Chemistry › Spectroscopy › Advanced Proteomics Techniques and Applications
  • Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
  • Health Sciences › Medicine › Surgery › Cholangiocarcinoma and Gallbladder Cancer Studies
Keywords
hepatocellular carcinoma, intrahepatic cholangiocarcinoma, liver cancer, tumor proteome, lipid metabolism, extracellular matrix, cancer diagnosis
MeSH terms
Bile Duct Neoplasms, Bile Ducts, Intrahepatic, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Retrospective Studies, Cholangiocarcinoma, Proteome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review